Table 2.

csDMARDs in current development, phase, status and mechanism of action

Molecule	Mechanism of action	Pharmaceutical company/academy	Indications (axSpA/PsA)	Current development phase	Current development stage	Clinical trial no
Iguratimod*	Cox2 inhibitor TNF inhibitor	Qilu Hospital of Shandong University	axSpA	III	Recruiting	ChiCTR2000029112

*Marketed in China.

axSpA, axial spondyloarthritis; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; PsA, psoriatic arthritis.